Cancer misdiagnosed? How a second opinion can help you

get-a-second-opinionOur experience is that misdiagnosis is relatively common –  occurring in 50+ % of patients who present to us.

It is therefore likely they will have received the wrong treatments, impacting prognosis.

We are devoted to help patients get a second opinion –  we find, in many cases, this is the beginning of a second chance at life.

Indeed, a second opinion, using advanced genomic diagnostic tests, has led to a second chance at life for many of our cancer patients.

After watching our video animation scroll the page to see how Genomic Testing with ‘Next Generation Sequencing’ enables increased diagnostic accuracy.

More cases of Misdiagnosis – Our UK Colleagues have similar misdiagnosis observations…
E:G: Cancer Concierge in Harley Street state

In up to 69% of cases a second opinion has resulted in a change in diagnosis, treatment recommendations or prognosis.

Study: Journal of Cancer Research & Clinical Oncology study – showed between 18-47 % patients could be left with the wrong diagnosis, wrong treatment plan, ultimately affecting prognosis.

More Studies
Another Study suggests ” More than 90% of all NET (neuro-endocrine tumours like Steve Jobs) patients are incorrectly diagnosed and initially treated for the wrong disease.

Misdiagnoses or delayed diagnoses mean that NET patients are treated on average five to seven years for the wrong disease; often the correct diagnosis is not made until the disease has spread and advanced.

And another Study  – Shows how genetic profiling can help find CUPs (cancer of unknown primaries) Genetic Profiling of Cancers of Unknown Primary Improves Tx AMSTERDAM ― If the primary tumour site is unknown, identifying the molecular profile of the metastatic tumour is essential to choosing appropriate therapy, and this is becoming increasingly possible, a US researcher reported at European Cancer Congress 2013 (ECCO-ECMO-ESTRO).

“We are absolutely sure that just finding the tissue of origin and the histological subtype is truly insufficient to guide therapy,” Zoran Gatalica, MD, DSc, executive medical director, Caris Life Sciences, Phoenix, Arizona, commented at a press briefing.

“There is definitely a need for finding genetic alterations that could prove useful in selecting targeted therapies.”

lets_get_it_right_logoThe Grace Gawler Institute employs a Forensic Approach  (no stone un-turned) to ensure the patient’s original diagnosis is correct.

For the last decade, this has involved genomic tests. Originally we used large pathology lab’s in Europe and the USA, now we have found a world certified Brisbane lab who we can work closely with on behalf of our patients – a win-win for everyone.

These advanced (genomic) oncology tests utilise ‘Next Generation Sequencing’ that precisely identifies the right drug for cancer type – thereby increasing chances of successful treatment.

Once a correct diagnosis is established we organise referrals to innovative cancer specialists (nationally or internationally) which offer the best treatments for the particular cancer and circumstances.

We facilitate consultations or remote medical record reviews to confirm you are on the best possible treatment path, as cancer is a complex and very individualised condition.

We also act as case managers, while you are at home or overseas.

There are many cases where the genomic diagnostic tests identify a drug-based treatment (approved in the USA or Europe), which is not available in Australia or the UK or another home country.

With the approval of your local oncologist, we can arrange the purchase and delivery for many of these medicines. After all we live in a global village, we buy many articles from other countries via the Internet, why shouldn’t it apply to medicines – especially when a patient’s life is on the line.

targeted-cancer-testThe diagram from Oncofocus® (UK colleagues) is typical of new genetic tests that match the patient’s cancer with the right targeted therapy. We employ similar in Australia and Australasia.

The test works by firstly sequencing the DNA and RNA of a patient’s tumour which has been extracted from the routine histology sample used for diagnosis.

Oncofocus®’s claim for an 80% response rate (is supported by our experience) using high quality genomic tests. Note the poor response rate (2-16%) for therapies without testing. Oncofocus®

Contact Grace Gawler Now